Eryc 125

   
Google
 
Web NewDrugInformation.com

Eryc 125


Drug - Eryc 125
The trade name of the product as shown on the labeling.

Dosage - CAPSULE, DELAYED REL PELLETS; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Erythromycin
Multiple ingredients are in alphabetical order.

Strength - 125MG
The potency of the active ingredient(s), Erythromycin. May repeat for multiple part products.

Applicant - PARKE DAVIS
The firm name holding legal responsibility for Eryc 125. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 062648
The FDA assigned number to Eryc 125. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Eryc 125. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Oct 24, 1985
The date Eryc 125 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Eryc 125. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Eryc 125 is in. Format is RX, OTC, DISCN.

Applicant Full Name - Parke Davis Div Warner Lambert Co
The full name of the firm holding legal responsibility for the new application of Eryc 125.

Eryc 125